We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $250M
1-Year Est. Return 77.6%
This Fund
S&P 500
This Quarter Est. Return
-2.38%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$85.4M
AUM Growth
–
Cap. Flow
+$87.1M
Cap. Flow %
102.07%
Top 10 Hldgs %
94.55%
Holding
13
New
13
Increased
–
Reduced
–
Closed
–

Top Buys

1
VNDA icon
Vanda Pharmaceuticals
VNDA
+$19.1M
2
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$14.3M
3
SCLN
Sciclone Pharmaceuticals Inc
SCLN
+$9.84M
4
TBRA
Tobira Therapeutics, Inc. Common Stock
TBRA
+$8.66M
5
PTX
Pernix Therapeutics Holdings, Inc.
PTX
+$7.51M

Top Sells

No sells this quarter

Sector Composition

1 Healthcare 91.37%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VNDA icon
1
Vanda Pharmaceuticals
VNDA
$327M
$17.9M 20.93%
+1,918,929
New +$19.1M
CTIC
2
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$13.2M 15.42%
+1,069,862
New +$14.3M
SCLN
3
DELISTED
Sciclone Pharmaceuticals Inc
SCLN
$10.8M 12.67%
+1,175,574
New +$9.84M
TBRA
4
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
$8.38M 9.81%
+833,377
New +$8.66M
SGNT
5
DELISTED
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
$7.36M 8.63%
+462,824
New +$7.29M
PTX
6
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
$7.33M 8.59%
+248,465
New +$7.51M
FLNA
7
Filana Therapeutics
FLNA
$51.2M
$6.26M 7.33%
+510,714
New +$6.76M
FMI
8
DELISTED
Foundation Medicine, Inc.
FMI
$3.64M 4.27%
+173,049
New +$3.34M
VCEL icon
9
Vericel Corp
VCEL
$2.38B
$3.55M 4.16%
+1,376,887
New +$3.08M
ENTA icon
10
Enanta Pharmaceuticals
ENTA
$400M
$2.35M 2.75%
+71,147
New +$2.32M
DSCI
11
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$2.32M 2.72%
+507,799
New +$2.41M
CUTR
12
DELISTED
Cutera, Inc.
CUTR
$1.28M 1.5%
+100,000
New +$1.35M
SCTL
13
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$1.05M 1.23%
+130,345
New +$1.14M

Similar funds

BIA
Bigelow Investment Advisors Portland, Maine $250M AUM 19.33% 1-Year Est. Return
TGP
TMT General Partner Hong Kong $250M AUM 6.05% 1-Year Est. Return
ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
VM
VPR Management Houston, Texas $250M AUM 34.13% 1-Year Est. Return
PF
Parker Financial Silverdale, Washington $250M AUM 14.69% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
CWM
Chicago Wealth Management Chicago, Illinois $251M AUM 45.31% 1-Year Est. Return

Stonepine Capital Management's Q4 2015 Portfolio in Review

Q4 2015 is the first quarter with a 13F filing on record for Stonepine Capital Management, which disclosed 13 positions worth $85.4M. Its ten largest holdings account for 95% of the portfolio.

Its largest position is Vanda Pharmaceuticals: 1,918,929 shares worth $17.9M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets.

  • Stonepine Capital Management's largest Q4 2015 buy was Vanda Pharmaceuticals: 1,918,929 shares worth $17.9M.
  • Stonepine Capital Management's ten largest holdings make up 95% of its $85.4M portfolio in Q4 2015.
  • Stonepine Capital Management disclosed 13 positions in Q4 2015, its first 13F filing on record.

Based on Stonepine Capital Management's 13F filing for Q4 2015, filed 11 Feb 2016.